NasdaqGS:ATRA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Atara Biotherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATRA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-16.0%

ATRA

0.07%

US Biotechs

2.9%

US Market


1 Year Return

-56.2%

ATRA

23.9%

US Biotechs

8.9%

US Market

Return vs Industry: ATRA underperformed the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: ATRA underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

ATRAIndustryMarket
7 Day-16.0%0.07%2.9%
30 Day13.7%4.8%10.6%
90 Day-22.4%10.5%5.1%
1 Year-56.2%-56.2%25.1%23.9%11.4%8.9%
3 Year-24.8%-24.8%32.9%28.5%34.3%25.4%
5 Year-79.9%-79.9%-4.4%-10.0%60.7%42.7%

Price Volatility Vs. Market

How volatile is Atara Biotherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atara Biotherapeutics undervalued compared to its fair value and its price relative to the market?

13.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ATRA ($9.67) is trading below our estimate of fair value ($11.1)

Significantly Below Fair Value: ATRA is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ATRA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ATRA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRA is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Atara Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

25.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ATRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ATRA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATRA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Atara Biotherapeutics performed over the past 5 years?

-40.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRA is currently unprofitable.

Growing Profit Margin: ATRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATRA is unprofitable, and losses have increased over the past 5 years at a rate of -40.6% per year.

Accelerating Growth: Unable to compare ATRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ATRA has a negative Return on Equity (-117.96%), as it is currently unprofitable.


Next Steps

Financial Health

How is Atara Biotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ATRA's short term assets ($229.2M) exceed its short term liabilities ($31.5M).

Long Term Liabilities: ATRA's short term assets ($229.2M) exceed its long term liabilities ($15.2M).


Debt to Equity History and Analysis

Debt Level: ATRA is debt free.

Reducing Debt: ATRA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATRA has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ATRA is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?

8.62%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Pascal Touchon (56yo)

1

Tenure

US$6,865,307

Compensation

Mr. Pascal Touchon has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 2019 and joined it in June 2019. He serves as Director of Cogen Therapeutics, Inc.  ...


CEO Compensation Analysis

Compensation vs Market: Pascal's total compensation ($USD6.87M) is above average for companies of similar size in the US market ($USD3.11M).

Compensation vs Earnings: Insufficient data to compare Pascal's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Pascal Touchon
President1yrUS$6.87m0.033% $230.5k
Utpal Koppikar
Senior VP & CFO2yrsUS$2.54m0.032% $223.5k
Joseph Newell
Executive VP & COO0.33yrUS$2.72m0.026% $179.5k
Eric Hyllengren
Head of Investor Relations & Financeno datano datano data
Amar Murugan
Senior VP & General Counsel0.17yrno datano data
Kerry Daly
Head of Corporate Communicationsno datano datano data
Steve Bertram
Senior Vice President of Global Human Resources3.83yrsno datano data
Manher Joshi
Senior VP & Chief Medical Officerno datano datano data
José Vidal
Senior Vice President of Quality Assurance & Process Sciences1.83yrsno datano data
Renu Vaish
Senior Vice President of Global Regulatory Affairs1.75yrsno datano data

1.8yrs

Average Tenure

49yo

Average Age

Experienced Management: ATRA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Pascal Touchon
President1yrUS$6.87m0.033% $230.5k
Beth Seidenberg
Independent Director7.83yrsUS$302.49k0.022% $150.6k
Eric Dobmeier
Independent Director5.25yrsUS$327.49k0.022% $154.6k
William Heiden
Independent Director4.58yrsUS$302.49k0.012% $82.1k
Matthew Fust
Independent Director6.25yrsUS$317.49k0.031% $211.2k
Ronald Renaud
Non-Executive Chairman0.17yrno datano data
Carol Gallagher
Lead Independent Directorno dataUS$332.49k0.12% $858.4k
Roy Baynes
Independent Director1.75yrsUS$293.62kno data
Maria Roncarolo
Director0.083yrno datano data

3.2yrs

Average Tenure

56yo

Average Age

Experienced Board: ATRA's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.5%.


Top Shareholders

Company Information

Atara Biotherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atara Biotherapeutics, Inc.
  • Ticker: ATRA
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$691.870m
  • Shares outstanding: 71.59m
  • Website: https://www.atarabio.com

Number of Employees


Location

  • Atara Biotherapeutics, Inc.
  • 611 Gateway Boulevard
  • Suite 900
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
AT2DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014
0HIYLSE (London Stock Exchange)YesCommon StockGBUSDOct 2014

Biography

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 04:39
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.